Hannah M Hollandsworth1, Siamak Amirfakhri1, Filemoni Filemoni1, Robert M Hoffman2, Justin Molnar3, Paul J Yazaki3, Michael Bouvet4. 1. Department of Surgery, University of California San Diego, San Diego, California; Moores Cancer Center, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California. 2. Department of Surgery, University of California San Diego, San Diego, California; Moores Cancer Center, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California; AntiCancer, Inc., San Diego, California. 3. Beckman Research Institute of the City of Hope, Department of Molecular Imaging and Therapy, Duarte, California. 4. Department of Surgery, University of California San Diego, San Diego, California; Moores Cancer Center, University of California San Diego, San Diego, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California. Electronic address: mbouvet@ucsd.edu.
Abstract
BACKGROUND: Tumor-associated glycoprotein (TAG)-72 is a pancarcinoma antigen that is overexpressed in greater than 80% of colorectal adenocarcinomas. CC49 is a TAG-72-specific antibody. The aim of the present study was to demonstrate selective imaging of colon tumors and metastases with the humanized TAG-72 antibody (anti-huCC49) conjugated to a near-infrared fluorophore in orthotopic mouse models. METHODS: Anti-huCC49 was conjugated to near-infrared dye IR800CW. Mouse imaging was performed with the Pearl Trilogy Small Animal and FLARE Imaging Systems. Subcutaneous mouse models of colon cancer cell line LS174T were used to determine the optimal dose of administration and timing of imaging. Orthotopic mouse models of LS174T were established by surgical orthotopic implantation of LS174T tumors onto the serosa of the cecum. Peritoneal carcinomatosis models were established by injection of LS174T cells into the peritoneum of nude mice. Mice were administered anti-huCC49-IR800 via tail vein injection. Mice were euthanized 72 h later and imaged after laparotomy. RESULTS: Subcutaneous LS174T xenografts demonstrated optimal tumor detection 72 h after administration with 50 μg anti-huCC49-IR800CW. Tumors were visualized with fluorescence imaging with a mean tumor-to-liver ratio of 7.39 (standard deviation: 2.76). In the orthotopic model, metastases smaller than 1 mm were fluorescently visualized that were invisible with bright light. CONCLUSIONS: Anti-huCC49-IR800CW provides sensitive and specific imaging of colon cancer and metastases at a submillimeter resolution in metastatic nude mice models. This provides a promising near-infrared probe for the imaging of colon cancer and metastases for preoperative diagnosis and fluorescence-guided surgery.
BACKGROUND:Tumor-associated glycoprotein (TAG)-72 is a pancarcinoma antigen that is overexpressed in greater than 80% of colorectal adenocarcinomas. CC49 is a TAG-72-specific antibody. The aim of the present study was to demonstrate selective imaging of colon tumors and metastases with the humanized TAG-72 antibody (anti-huCC49) conjugated to a near-infrared fluorophore in orthotopic mouse models. METHODS: Anti-huCC49 was conjugated to near-infrared dye IR800CW. Mouse imaging was performed with the Pearl Trilogy Small Animal and FLARE Imaging Systems. Subcutaneous mouse models of colon cancer cell line LS174T were used to determine the optimal dose of administration and timing of imaging. Orthotopic mouse models of LS174T were established by surgical orthotopic implantation of LS174T tumors onto the serosa of the cecum. Peritoneal carcinomatosis models were established by injection of LS174T cells into the peritoneum of nude mice. Mice were administered anti-huCC49-IR800 via tail vein injection. Mice were euthanized 72 h later and imaged after laparotomy. RESULTS: Subcutaneous LS174T xenografts demonstrated optimal tumor detection 72 h after administration with 50 μg anti-huCC49-IR800CW. Tumors were visualized with fluorescence imaging with a mean tumor-to-liver ratio of 7.39 (standard deviation: 2.76). In the orthotopic model, metastases smaller than 1 mm were fluorescently visualized that were invisible with bright light. CONCLUSIONS: Anti-huCC49-IR800CW provides sensitive and specific imaging of colon cancer and metastases at a submillimeter resolution in metastatic nude mice models. This provides a promising near-infrared probe for the imaging of colon cancer and metastases for preoperative diagnosis and fluorescence-guided surgery.
Authors: D C Slavin-Chiorini; S V Kashmiri; H S Lee; D E Milenic; D J Poole; E Bernon; J Schlom; P H Hand Journal: Cancer Biother Radiopharm Date: 1997-10 Impact factor: 3.099
Authors: Hannah M Hollandsworth; Thinzar M Lwin; Siamak Amirfakhri; Filemoni Filemoni; Surinder K Batra; Robert M Hoffman; Punita Dhawan; Michael Bouvet Journal: J Surg Res Date: 2019-05-09 Impact factor: 2.192
Authors: Sun Ok Yoon; Tae Sup Lee; Sang Jick Kim; Myung Hee Jang; Young Jun Kang; Jae Hyun Park; Keun-Soo Kim; Hyun Sil Lee; Chun Jeih Ryu; Noreen R Gonzales; Syed V S Kashmiri; Sang Moo Lim; Chang Woon Choi; Hyo Jeong Hong Journal: J Biol Chem Date: 2006-01-09 Impact factor: 5.157
Authors: Doreen M Agnese; Shahab F Abdessalam; William E Burak; Mark W Arnold; Denise Soble; George H Hinkle; Donn Young; M B Khazaeli; Edward W Martin Journal: Ann Surg Oncol Date: 2004-02 Impact factor: 5.344
Authors: Michael A Turner; Hannah M Hollandsworth; Hiroto Nishino; Siamak Amirfakhri; Thinzar M Lwin; Andrew M Lowy; Sukhwinder Kaur; Gopalakrishnan Natarajan; Kavita Mallya; Robert M Hoffman; Surinder K Batra; Michael Bouvet Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Hannah M Hollandsworth; Hiroto Nishino; Michael Turner; Siamak Amirfakhri; Filemoni Filemoni; Robert M Hoffman; Paul J Yazaki; Michael Bouvet Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Thinzar M Lwin; Michael A Turner; Siamak Amirfakhri; Hiroto Nishino; Robert M Hoffman; Michael Bouvet Journal: Cells Date: 2022-01-12 Impact factor: 6.600